中国国际金融股份有限公司 关于华厦眼科医院集团股份有限公司 2 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 11.其他（包括经营环境、业务发 | | | | 展、财务状况、管理状况、核心 | 无 | 不适用 | | 技术等方面的重大变化情况） | | | 2025 年半年度持续督导跟踪报告 | 保荐人名称：中国国际金融股份有限公司 | 被保荐公司简称：华厦眼科 | | --- | --- | | 保荐代表人姓名：周凌轩 | 联系电话：010-65051166 | | 保荐代表人姓名：赵冀 | 联系电话：010-65051166 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金管 | 是 | | 理制度、内控制度、内部审计制度、关 ...

Summary of Key Points Core Viewpoint - A total of 135 stocks received buy ratings from institutions today, with 17 stocks receiving initial attention from institutions, indicating a strong interest in the market and potential investment opportunities [1]. Institutional Ratings - 140 buy rating records were published today, with 29 of these providing future target prices. 13 stocks have an upside potential exceeding 20%, with AVIC Optoelectronics showing the highest potential at 61.62% [1]. - Notable stocks with high upside potential include Noli Shares at 48.46% and United Imaging Healthcare at 37.22% [1]. - 17 stocks received initial buy ratings from institutions, including Haimeixing and Hengli Hydraulic [1]. Market Performance - Stocks rated with buy ratings saw an average increase of 3.27%, outperforming the Shanghai Composite Index. 119 stocks experienced price increases, with several hitting the daily limit up [1]. - Stocks with significant declines included Noli Shares, Agricultural Bank, and Shoufang Environmental Protection, with declines of 3.23%, 2.93%, and 1.26% respectively [1]. Industry Focus - The most favored industries include power equipment and machinery, each with 17 stocks listed in the buy rating category. The pharmaceutical and communication sectors also attracted attention, with 15 and 6 stocks respectively [2]. - Specific stocks receiving multiple buy ratings include Betaini, Kebo Da, AVIC Optoelectronics, and Yunnan Baiyao, each with two buy ratings [2][3]. Detailed Stock Information - A selection of stocks with buy ratings includes: - Betaini (2 ratings, +2.22% today, PE 40.30) in beauty care - Kebo Da (2 ratings, +10.00% today, PE 27.44) in automotive - AVIC Optoelectronics (2 ratings, +0.57% today, PE 28.83) in defense and military [2][3]. - Other notable stocks include: - Yunnan Baiyao (2 ratings, +1.06% today, PE 14.56) in pharmaceuticals - Zhonglian Heavy Industry (2 ratings, +0.41% today, PE 11.39) in machinery [2][3]. Additional Stock Ratings - Additional stocks with single buy ratings include: - Xuji Electric (1 rating, +2.09% today, PE 18.44) in power equipment - Xugong Machinery (1 rating, -0.20% today, PE 13.29) in machinery - China Rare Earth (1 rating, +2.33% today, PE 174.07) in non-ferrous metals [3][4].

Group 1: Key Recommendations - Key recommendation for Kelun Pharmaceutical (002422): Short-term performance under pressure, but continuous innovation results are being realized [5][6][7][8] - Key recommendation for Huaxia Eye Hospital (301267): Good growth in refractive business, with performance stabilizing and improving [10][11][12][14] - Key recommendation for Pumen Technology (688389): Domestic business short-term decline, but international business shows steady growth [15][16][17][19] Group 2: Financial Performance - Kelun Pharmaceutical reported H1 2025 revenue of 9.083 billion yuan, down 23.20% year-on-year, and net profit of 1.001 billion yuan, down 44.41% year-on-year [5][6] - Huaxia Eye Hospital achieved H1 2025 revenue of 2.139 billion yuan, up 4.31% year-on-year, and net profit of 282 million yuan, up 6.20% year-on-year [10][11] - Pumen Technology's H1 2025 revenue was 507 million yuan, down 14.1% year-on-year, with a net profit of 122 million yuan, down 29.3% year-on-year [16][17] Group 3: Business Segments - For Kelun Pharmaceutical, the infusion segment saw revenue of 3.750 billion yuan, down 19.65% year-on-year, while innovative drug sales reached 310 million yuan, with SKB264 accounting for 97.65% of this [6][7] - Huaxia Eye Hospital's refractive project revenue was 789 million yuan, up 13.75% year-on-year, while cataract project revenue declined by 7.33% to 431 million yuan [12][13] - Pumen Technology's domestic revenue was 332 million yuan, down 22.74% year-on-year, while international revenue was 175 million yuan, up 9.01% year-on-year [17][18] Group 4: Investment Recommendations - Kelun Pharmaceutical's revenue forecasts for 2025-2027 are 19.471 billion, 22.371 billion, and 24.487 billion yuan, with net profits of 2.265 billion, 2.876 billion, and 3.418 billion yuan respectively, maintaining a "buy" rating [8] - Huaxia Eye Hospital's net profit forecasts for 2025-2027 are 515 million, 605 million, and 697 million yuan, also maintaining a "buy" rating [14] - Pumen Technology's net profit forecasts for 2025-2027 are 407 million, 471 million, and 537 million yuan, maintaining a "buy" rating [19]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][4] Core Views - The company's refractive business is experiencing good growth, leading to a stable and positive performance [1][4] - The company has achieved a revenue of 2.139 billion yuan in the first half of 2025, representing a year-on-year increase of 4.31%, and a net profit of 282 million yuan, up 6.20% year-on-year [4][5] - The company continues to expand its network of specialized eye hospitals and vision centers, with a total of 64 eye hospitals and 67 vision centers established across 19 provinces and municipalities [4][5] Summary by Sections Financial Performance - In Q2 2025, the company reported a revenue of 1.046 billion yuan, a decrease of 2.47% year-on-year, while the net profit for the same quarter was 132 million yuan, an increase of 20.73% year-on-year [4] - The gross profit margin for H1 2025 was 45.20%, a slight decrease of 0.64 percentage points year-on-year, while the net profit margin increased by 0.71 percentage points to 14.04% [4] Business Segments - The refractive segment generated revenue of 789 million yuan in H1 2025, a year-on-year increase of 13.75%, making it the main growth driver [4] - The cataract segment saw a revenue decline of 7.33% year-on-year, totaling 431 million yuan, primarily due to high base effects from the previous year [4] Growth Strategy - The company is focused on a dual strategy of "internal growth + external mergers and acquisitions," aiming to enhance its national presence in the eye care sector [4] - The company has introduced advanced surgical technologies and high-end artificial lenses to improve service quality and expand its offerings [4] Earnings Forecast - The company expects net profits of 515 million yuan, 605 million yuan, and 697 million yuan for the years 2025, 2026, and 2027, respectively, with corresponding EPS of 0.61 yuan, 0.72 yuan, and 0.83 yuan [5][6]

Core Viewpoint - The refractive surgery business, a significant revenue source for private ophthalmology institutions, has experienced a slowdown in growth in recent years [3]. Group 1: Revenue Growth Analysis - Among five listed ophthalmology companies in A-shares, three reported single-digit or less revenue growth in their refractive projects for the first half of the year. Specifically, Purui Eye Hospital (301239.SZ) saw a 4.13% increase to 720 million yuan, accounting for 49% of its total revenue; He’s Eye Hospital (301103.SZ) reported a 3.26% increase to 135 million yuan, making up 24% of its revenue; and Guangzheng Eye Hospital (002524.SZ) had a mere 0.32% growth to 142 million yuan, representing 32.71% of its revenue [4]. - In contrast, Aier Eye Hospital (300015.SZ) and Huaxia Eye Hospital (301267.SZ) maintained double-digit growth rates of 11.4% and 13.75%, respectively [4]. Group 2: Market Dynamics and Competition - The refractive surgery market is highly competitive, prompting ophthalmology companies to leverage new technologies for differentiation [6]. - Aier Eye Hospital attributed its revenue growth to the acceptance of new surgical techniques such as All-Laser LASIK and the expansion of its medical network, which increased patient coverage [8]. - Purui Eye Hospital is also focusing on introducing authoritative expert teams and upgrading high-end diagnostic equipment to cultivate new growth points [8]. Group 3: Consumer Demand and Market Potential - The current demographic for refractive surgery includes two main groups: those with essential needs due to academic or professional requirements and those seeking aesthetic improvements by eliminating glasses or contact lenses [8]. - Despite the stable demand from the essential needs group, macroeconomic factors have lengthened the decision-making cycle for non-essential consumers [8]. - There remains significant unmet demand in the refractive surgery market, with approximately 700 million people suffering from myopia in China, yet only about 1 million undergoing surgery annually, indicating substantial growth potential [8]. Group 4: Technological Innovations - Recent reports indicate that Generation Z has a personalized and urgent demand for vision correction, driving innovation and iteration in refractive surgery technologies [9]. - Aierkan has introduced new refractive surgery solutions, such as All-Laser LASIK, which utilizes various data for personalized treatment. Since its launch at the 2023 China International Import Expo, over 50,000 surgeries have been performed, with more than 100 hospitals equipped with the technology [10].

Core Insights - The conference held by Huaxia Eye Hospital Group focused on advancing myopia prevention strategies and enhancing service quality, aiming for high-quality development in myopia control in China [1][4][6] Group 1: Conference Highlights - The "2025 Autumn Myopia Prevention Work Promotion Conference" took place in Nanjing, gathering leaders and representatives to discuss strategies for myopia prevention [1] - The launch of the "11th National Myopia Prevention Awareness Month" and the "Multi-City Action for Children's Eye Health" initiative aims to create a nationwide public welfare platform for children's eye health services [2] - 45 hospitals were recognized for their exemplary campus screening services, receiving awards for their contributions to public welfare in myopia prevention [3] Group 2: Strategic Development - The conference emphasized the importance of internal development as a foundation for enhancing core competitiveness and service quality [4] - Group leaders outlined a transformation strategy focusing on proactive adaptation and deepening internal development to navigate market changes [4] - Key implementation points were discussed, including quality improvement in screenings, talent optimization, brand collaboration, AI technology integration, and the establishment of a "5 Action Plan" [4][5] Group 3: Innovation and Technology - The "Eye Care通" platform was showcased for its role in utilizing big data to optimize business processes and enhance service experiences [5] - The focus on adult visual management needs was highlighted, with solutions presented to bridge the gap in myopia prevention implementation [5] Group 4: Commitment and Accountability - The conference included a recognition ceremony for outstanding teams and individuals in myopia prevention, reinforcing commitment to goals through the signing of responsibility agreements [6] - A total of 15 core work consensus points were established, marking a transition from discussion to actionable execution [7]

Group 1: Industry Overview - The ophthalmology sector is experiencing significant performance differentiation among listed companies, with a competitive landscape evolving rapidly [1][2] - The Chinese ophthalmology medical service market is projected to reach 223.1 billion yuan in 2024, growing at 11.05% year-on-year, with private institutions holding a 42% market share [3] - The refractive and cataract surgery segments account for 47% of the overall market, with refractive surgery alone reaching a market size of 73 billion yuan [3] Group 2: Company Performance - Aier Eye Hospital leads the industry with a revenue of 11.507 billion yuan, showcasing strong market competitiveness, while Huaxia and Puri Eye Hospitals follow with revenues exceeding 1.4 billion yuan [1] - Aier Eye Hospital's net profit stands at 2.051 billion yuan, but its growth rate has slowed to 0.05%, while He Eye Hospital achieved a remarkable net profit growth of 84.19% [1] - Puri Eye Hospital reported a significant decline in net profit by 66.12%, indicating challenges in profitability [1] Group 3: Competitive Dynamics - The competition in the ophthalmology sector is intensifying, with an increasing number of private eye hospitals and supportive government policies encouraging private capital participation [2] - The cataract surgery segment is facing revenue pressures due to policy changes, including centralized procurement and DRG/DIP payment reforms, leading to revenue declines for several companies [4] - The industry is entering a "red ocean" phase, with rapid increases in capacity and competition among private eye hospitals [4][5] Group 4: Strategic Responses - Companies are focusing on mergers and acquisitions to expand their market presence, with Aier Eye Hospital acquiring three companies in the first half of 2025 [6] - Huaxia Eye Hospital is enhancing its management and service processes while accelerating the construction of hospitals and optical centers [6] - He Eye Hospital is expanding its franchise model, signing 23 new contracts in the first half of 2025 [6] Group 5: Technological Innovation - Technological innovation is becoming a key competitive advantage, particularly in the refractive surgery segment, where new techniques are being rapidly adopted [7][8] - Aier Eye Hospital's refractive project revenue grew by 11.14%, driven by the promotion of new surgical techniques [7] - The demand for personalized vision correction among the Z generation is pushing for rapid innovation in refractive surgery technologies [8][9] Group 6: Market Challenges - The expansion trend in the ophthalmology market is reversing, with some less competitive hospitals closing due to increased competition and economic pressures [5] - Companies face challenges in balancing expansion with cost control, particularly regarding goodwill and operational costs [6] - The market for refractive surgery is characterized by a need for patient education and awareness, as patients often rely on personal recommendations rather than solely on physician advice [10]

Core Viewpoint - The ophthalmology medical industry is experiencing a slowdown in the growth of refractive surgery revenue, with many companies reporting single-digit growth rates in this segment, while a few are still achieving double-digit growth. Group 1: Industry Overview - The refractive surgery business, a significant revenue source for private ophthalmology institutions, has shown a general trend of slowing growth in recent years [1] - Among five listed ophthalmology companies in A-shares, three reported refractive project revenue growth at single-digit levels or below in the first half of the year [1] - Specific growth figures include: - Puyi Eye Hospital (301239.SZ) with a 4.13% increase to 720 million yuan, accounting for 49% of total revenue [1] - He’s Eye Hospital (301103.SZ) with a 3.26% increase to 135 million yuan, accounting for 24% of total revenue [1] - Guangzheng Eye Hospital (002524.SZ) with a 0.32% increase to 142 million yuan, accounting for 32.71% of total revenue [1] - Aier Eye Hospital (300015.SZ) and Huaxia Eye Hospital (301267.SZ) are exceptions, achieving revenue growth rates of 11.4% and 13.75%, respectively [1] Group 2: Company Strategies - Aier Eye Hospital attributes its revenue growth in refractive projects to the acceptance of new surgical techniques such as All-Laser LASIK and the expansion of its medical network, enhancing patient coverage [3] - Puyi Eye Hospital is focusing on introducing authoritative expert teams and updating high-end diagnostic equipment to cultivate new growth points in the competitive refractive and vision care market [3] Group 3: Market Demand and Trends - The current refractive surgery patient population is divided into two categories: those with essential needs due to academic or professional requirements and those seeking aesthetic improvements [4] - Despite a stable demand from the essential needs group, the decision-making cycle for non-essential consumers is lengthening due to macroeconomic factors [4] - There is significant unmet demand in the refractive surgery market, with approximately 700 million myopic patients in China, but only about 1 million undergoing surgery annually [4] - The Z generation shows a personalized and urgent demand for vision correction, driving innovation and iteration in refractive surgery technologies [4] - Aierkon has introduced new refractive surgery solutions, such as All-Laser LASIK, which allows for personalized treatment based on various eye data [4] Group 4: Technology Adoption - Aierkon's All-Laser LASIK equipment has seen over 50,000 surgeries performed since its launch at the 2023 China International Import Expo, with over 100 hospitals equipped nationwide [5] - The company emphasizes the need for continued market education to enhance the penetration of new technologies [5]

Core Viewpoint - The refractive surgery business of private ophthalmology medical institutions is experiencing a slowdown in revenue growth, with several companies reporting single-digit growth rates in their refractive project revenues [1][2]. Group 1: Revenue Growth Analysis - Among five listed ophthalmology medical companies, three reported refractive project revenue growth at single-digit levels or below in the first half of the year. Specifically, Purui Eye Hospital (301239.SZ) saw a 4.13% increase to 720 million yuan, accounting for 49% of its total revenue; He’s Eye Hospital (301103.SZ) reported a 3.26% increase to 135 million yuan, making up 24% of its revenue; and Guangzheng Eye Hospital (002524.SZ) had a 0.32% increase to 142 million yuan, representing 32.71% of its revenue [1]. - In contrast, Aier Eye Hospital (300015.SZ) and Huaxia Eye Hospital (301267.SZ) managed to maintain double-digit growth rates in their refractive project revenues, with increases of 11.4% and 13.75%, respectively [1]. Group 2: Competitive Strategies - To navigate the competitive refractive surgery market, companies are leveraging new technologies. Aier Eye Hospital reported that its revenue growth in refractive projects is driven by the acceptance of new surgical techniques such as all-laser and full-femtosecond procedures, which have improved the business structure and increased average prices [2]. - Purui Eye Hospital is also responding to market competition by continuously introducing authoritative expert teams and updating high-end diagnostic equipment to cultivate new growth points [2]. Group 3: Market Demand and Trends - The current refractive surgery patient population can be divided into two groups: one with essential needs due to academic or professional requirements, and another seeking aesthetic improvements by eliminating glasses or contact lenses [2]. - Despite the large number of myopic patients in China, estimated at around 700 million, only about 1 million undergo refractive surgery annually, indicating significant unmet demand and potential for market penetration [3]. - The Z generation shows a personalized and urgent demand for vision correction, pushing for technological innovation and customization in refractive surgery [3].

Macro Strategy - The central government's budget for 2025 is expected to increase by 282.5 billion yuan, with significant growth in defense spending (119.5 billion yuan), debt interest payments (77.2 billion yuan), and scientific research (36.2 billion yuan) [1] Fixed Income - The convertible bond market is experiencing accumulating divergences, with a recommendation to reduce exposure to high-priced targets while increasing ETF allocations to balance risks [2] - The yield on 10-year government bonds rose by 4 basis points to 1.785% during the week of August 18-22, 2025 [3] Green Bonds - In the week of August 18-22, 2025, 16 green bonds were issued in the interbank and exchange markets, totaling approximately 6.79 billion yuan, a decrease of 6.34 billion yuan from the previous week [4] Company Analysis Top Group (601689) - The company's net profit forecast for 2025-2026 has been revised down to 3.358 billion yuan and 4.312 billion yuan, respectively, due to intense industry competition and a decline in profitability [5] Xusheng Group (603305) - The net profit forecast for 2025-2027 has been adjusted to 500 million yuan, 605 million yuan, and 750 million yuan, reflecting a decrease due to declining sales from major clients and fierce competition [6] China Galaxy (601881) - The net profit forecast for 2025-2027 has been raised to 13 billion yuan, 14 billion yuan, and 14.9 billion yuan, with a year-on-year growth of 30%, 7%, and 7% respectively [7] Better Ray (835185) - The net profit forecast for 2025-2027 remains at 1.2 billion yuan, 1.51 billion yuan, and 1.8 billion yuan, with year-on-year growth of 29%, 25%, and 19% [8] Nanwang Energy (003035) - The company achieved a revenue of 1.603 billion yuan in the first half of 2025, a year-on-year increase of 21.1%, and a net profit of 214 million yuan, up 4.5% [9] Chip Source Micro (688037) - The company reported a significant improvement in Q2 2025, with a revenue of 430 million yuan, a year-on-year decrease of 3.5%, but a quarter-on-quarter increase of 57.6% [10] Xinhua Du (002264) - The company reported a revenue of 1.86 billion yuan in the first half of 2025, a year-on-year decrease of 11%, but a net profit of 147 million yuan, an increase of 1.2% [11] Zhongmin Energy (600163) - The net profit forecast for 2025-2027 is maintained at 920 million yuan, 1 billion yuan, and 1.04 billion yuan, with a PE ratio of 11.2, 10.3, and 9.9 [12] Water Well Square (600779) - The company reported a revenue of approximately 1.498 billion yuan in the first half of 2025, a year-on-year decline of 12.8%, and a net profit of approximately 105 million yuan, a decline of 56.5% [13] China Heavy Truck (000951) - The net profit forecast for 2025-2027 has been revised down to 1.658 billion yuan, 1.894 billion yuan, and 2.165 billion yuan due to expected declines in heavy truck exports to Russia [14] Juewei Food (603517) - The company maintains its previous profit forecast, expecting net profits of 400 million yuan, 510 million yuan, and 560 million yuan for 2025-2027, with year-on-year growth of 77%, 26%, and 10% [15] Old White Dry Wine (600559) - The company reported a revenue of 2.48 billion yuan in the first half of 2025, a year-on-year increase of 0.5%, and a net profit of 320 million yuan, an increase of 5.4% [16] Chinese Online (300364) - The company is undergoing a critical transformation period, with a focus on new business investments, leading to a downward adjustment in profit forecasts for 2025-2026 [17] China Pacific Insurance (601601) - The net profit forecast for 2025-2027 has been raised to 51.6 billion yuan, 52.7 billion yuan, and 55.3 billion yuan, reflecting a positive outlook on high-quality development [18] Guomao Co., Ltd. (603915) - The net profit forecast for 2025-2027 is maintained at 300 million yuan, 343 million yuan, and 400 million yuan, with a focus on enhancing competitiveness through new product launches [19] Huazhong CNC (300161) - The net profit forecast for 2025-2027 has been adjusted to 70 million yuan, 131 million yuan, and 197 million yuan, reflecting a cautious outlook on the high-end CNC system market [20] New Energy (02688.HK) - The net profit forecast for 2025-2027 has been adjusted to 70.9 billion yuan, 74.2 billion yuan, and 78.0 billion yuan, reflecting a stable growth outlook [21]